Moleculin Biotech, Inc. MBRX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.10M | 2.49M | 2.41M | 2.15M | 2.09M |
| Depreciation & Amortization | 8.00K | 8.00K | 9.00K | 21.00K | 29.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.56M | 7.87M | 7.53M | 5.91M | 5.72M |
| Operating Income | -7.56M | -7.87M | -7.53M | -5.91M | -5.72M |
| Income Before Tax | -7.64M | -12.85M | 15.55M | -25.40M | -17.81M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.64M | -12.85M | 15.55M | -25.40M | -17.81M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.64M | -12.85M | 15.55M | -25.40M | -17.81M |
| EBIT | -7.56M | -7.87M | -7.53M | -5.91M | -5.72M |
| EBITDA | -7.55M | -7.87M | -7.52M | -5.88M | -5.69M |
| EPS Basic | -28.04 | -70.85 | 137.99 | -340.43 | -573.50 |
| Normalized Basic EPS | -16.80 | -38.93 | 86.83 | -212.77 | -358.44 |
| EPS Diluted | -28.04 | -70.85 | 137.99 | -340.43 | -573.50 |
| Normalized Diluted EPS | -16.80 | -38.93 | 86.83 | -212.77 | -358.44 |
| Average Basic Shares Outstanding | 284.00K | 206.20K | 111.90K | 74.60K | 31.10K |
| Average Diluted Shares Outstanding | 284.00K | 206.20K | 111.90K | 74.60K | 31.10K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |